Medicinal aerosol formulations
AssigneeJago Research AG
InventorsManfred Keller, Kurt Herzog, Rudi Müller-Walz, Holger Kraus
Life of this patent
Estimating the term…
Abstract
The use of solid, pharmaceutically acceptable salts of cromoglycic acid and/or nedocromil as carriers in a therapeutically and prophylactically inefficacious amount in suspension aerosol formulations of pharmaceutical active compounds improves the dispersion properties, increases the chemical and physical stability of moisture-sensitive active compounds, makes possible a more accurate dosage, in particular even of low-dose active compounds, and as a rule permits the abandonment of surface-active agents.
Claims25
A medicinal aerosol formulation, comprising a solid, pharmaceutically acceptable salt of at least one compound selected from the group consisting of cromoglycic acid and nedocromil, in a therapeutically and prophylactically inefficacious amount in the range from 5 to 250 μg per puff of spray, an efficacious amount of a finely divided pharmaceutically active compound which is different from said salt, having a mean particle diameter of less than 6 μm, and a non-toxic liquid propellant, in which said active compound is present in suspended form.
A method of improving dosage accuracy of a medicinal suspension aerosol formulation comprising a finely divided pharmaceutically active compound having a mean particle diameter of less than 6 μm, and a non-toxic liquid propellant, in which the active compound is present in suspended form, said method comprising adding to said formulation a solid, pharmaceutically acceptable salt of at least one compound selected from the group consisting of cromoglycic acid and nedocromil, in a therapeutically and prophylactically inefficacious amount.
A method of reducing moisture sensitivity of a suspended pharmaceutically active compound in a medicinal suspension aerosol formulation comprising said pharmaceutically active compound in finely divided form having a mean particle diameter of less than 6 μm, and a non-toxic liquid propellant, in which said active compound is present in suspended form, said method comprising adding to said formulation a solid, pharmaceutically acceptable salt of at least one compound selected from the group consisting of cromoglycic acid and nedocromil, in a therapeutically and prophylactically inefficacious amount.
Dependencies are inferred from the claim text.